Standard lipid panels may be telling an incomplete story for postmenopausal women taking polyphenol supplements. When cholesterol numbers rise alongside a simultaneous drop in oxidized LDL, the clinical interpretation becomes far more nuanced than conventional cardiovascular risk screening typically captures — a distinction with real implications for the millions of women navigating cardiometabolic changes after menopause.
The PolyPAUSE trial enrolled 90 mildly hypercholesterolemic, non-medicated postmenopausal women in a randomized, placebo-controlled crossover design. Participants received a daily combination of ellagitannins plus ellagic acid (~312 mg), resveratrol (~133 mg), and isoflavones (~166 mg) for eight weeks, separated from placebo by a four-week washout. In roughly 80% of completers, total cholesterol rose by 7%, LDL-cholesterol by 9.5%, and triglycerides by 16% — increases that tracked with age. Yet oxidized LDL declined significantly, apolipoprotein B trended toward reduction, and inflammatory and bone markers remained unchanged. Crucially, gut microbiota metabotypes — urolithin producers, equol producers, and lunularin producers — appeared to modulate how individuals responded, stratified using high-resolution mass spectrometry.
This finding sits at a productive tension in polyphenol research. Oxidized LDL, not LDL particle count alone, is increasingly recognized as the atherogenic fraction most directly implicated in foam cell formation and plaque initiation. A scenario where total LDL rises but its oxidative vulnerability falls could represent a net neutral or even favorable shift in cardiovascular risk — though this remains unconfirmed by hard endpoint data. The metabotype stratification is particularly valuable: it underscores that polyphenol bioavailability is profoundly microbiome-dependent, which likely explains much of the inconsistency across prior human trials. Key limitations include the eight-week duration, the absence of imaging or event-based outcomes, and the single-compound mixture making individual contribution attribution impossible. This is incremental but methodologically rigorous work that meaningfully advances mechanistic understanding of polyphenols in a high-risk population.
